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Original research article—Basic science
Elevation in Cell Cycle and Protein Metabolism Gene 
Transcription in Inactive Colonic Tissue From Icelandic Patients 
With Ulcerative Colitis
Mathena Vinayaga-Pavan, MRCP,*,  Matthew Frampton, PhD,† Nikolas Pontikos, PhD,‡,   
Adam P. Levine, MBBS PhD,† Phillip J. Smith, MRCP,† Jon G. Jonasson, MD,§,¶ Einar S. Björnsson, MD PhD,¶,‖ 
Anthony W. Segal, MD PhD,† and Andrew M. Smith, PhD*,†
Background: A combination of genetic and environmental factors is thought to be involved in the pathogenesis of ulcerative colitis (UC). In 
Iceland, the incidence of UC is one of the highest in the world. The aim of this study was to characterize patients with UC and identify potential 
germline mutations and pathways that could be associated with UC in this population.
Methods: Exome sequencing and genome-wide microarray analysis on macroscopically noninflamed colonic mucosa from patients and controls 
were performed. Exome sequence data were examined for very rare or novel mutations that were over-represented in the UC cohort. Combined 
matching of variant analysis and downstream influence on transcriptomic expression in the rectum were analyzed.
Results: One thousand eight hundred thirty-eight genes were differentially expressed in rectal tissue from UC patients and identified an upregulation in 
genes associated with cell cycle control and protein processing in the endoplasmic reticulum (ER). Two missense mutations in thiopurine S-methyltransferase 
(TPMT) with a minor allele frequency of 0.22 in the UC patients compared with a reported 0.062 in the Icelandic population were identified. A predicted 
damaging mutation in the gene SLC26A3 is potentially associated with increased expression of DUOX2 and DUOXA2 in rectal tissue.
Conclusions: Colonic mucosa of UC patients demonstrates evidence of an elevation in genes involving cell proliferation and processing of 
proteins within the ER. Exome sequencing identified a possible increased prevalence of 2 damaging TPMT variants within the UC population, 
suggesting screening the UC population before initiation of thiopurine analogue therapy to avoid toxicity associated with these mutations.
Key Words: microarray, inflammatory bowel disease, rectum, TPMT.
INTRODUCTION
Ulcerative colitis (UC) is a chronic immune-mediated 
condition primarily affecting the colonic epithelium. The pur-
suit of the genetic contribution to this disease has, in recent 
years, focused on several large-scale genome-wide association 
studies (GWAS), with >240 risk loci for inflammatory bowel 
disease (IBD) identified to date.1 Of the 240 loci identified, 
only 28 are specific to UC, with 141 being also being associ-
ated with Crohn’s disease.2 Indeed, estimates of the genetic 
correlation suggest only a small influence on disease variance.3 
The reduction of costs in technology facilitating assessment 
of larger quantities of genetic data allows multi-omic data to 
be used to investigate missing heritability and possible envi-
ronmental factors contributing to disease. The transcriptomic 
alterations within the inflamed colonic mucosa in IBD have 
been well documented, and a meta-analysis conducted by 
Clark et  al. combined 6 independent microarray data sets 
and performed a comprehensive bioinformatic analysis.4 
Consistent with genome-wide association study (GWAS) data, 
cellular processes relating to immune defense response, leu-
kocyte activation, cell proliferation, and response to bacterial 
components were identified. Previous studies on noninflamed 
colonic mucosa from UC patients have identified a number of 
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protein/retinoic acid–inducible neural specific 3 (BRINP3),5 
but all of these studies have been conducted on patients with 
varying degrees of underlying microscopic inflammation and a 
mixed ethnicity that was not genetically verified. This heteroge-
neity may impact on the ability to identify subtle but relevant 
changes to the mucosal tissue.
Ulcerative colitis has an incidence of 16.5 per 100,000 
in the population of Iceland, equating to one of the highest 
incidence in the world.6 The most recent nationwide popula-
tion-based study of the incidence of IBD in Iceland between 
1995 and 2009 identified a significant increase in UC over the 
study period, whereas Crohn’s disease remained stable, with a 
much lower incidence of 6.6 per 100,000.7 The population of 
Iceland is approximately 340,000,8 and genetic studies have 
revealed a reduced genetic heterogeneity, with genetic drift hav-
ing a greater impact on the genetic variation when compared 
with other European countries due to geographic, and hence 
reproductive, isolation.9 A previous study into the genetic con-
tribution to IBD in the Icelandic population identified a high 
degree of familial aggregation that extended beyond the nuclear 
family.10 These findings suggest that a genetic predisposition in 
combination with a potential environmental effect is likely to 
be driving the increased prevalence of UC in this population.
This study aims to combine exome sequencing of genomic 
DNA and transcriptomic data from noninflamed colonic 
mucosal tissue collected from well characterized Icelandic UC 
patients and ethnically matched healthy controls. The data will 
be used to identify novel genetic variants and transcriptomic 
signatures that will improve our understanding of the etio-
pathogenesis of the disease and potentially highlight new ther-
apeutic targets.
METHODS
Patient Recruitment, Ethics, and Tissue 
Collection
All patients were recruited from the Gastroenterology and 
Hepatology Department at the Landspitali University Hospital 
Hringbraut, Reykjavik, Iceland. Ulcerative colitis patients had 
histologically confirmed disease before recruitment. Consent 
was obtained under approval from the Bioethics Committee of 
Iceland (application number VSNb2011080005/03.15) and the 
Data Protection Authority of Iceland. Healthy controls (HCs) 
were recruited from individuals undergoing colonoscopy, 
matched for sex and age (±5 years) (Table 1). Biopsies were col-
lected during routine colonoscopies and were performed on UC 
patients undergoing surveillance. All patients had clinically qui-
escent disease for a minimum of 3 months before the procedure 
and upon inspection had a MAYO endoscopic score assessed 
as ≤1.11 Paired endoscopic pinch biopsies (Olympus biop-
sy-forceps, FB-24U-1) were obtained from the ascending colon 
and rectum. One biopsy was placed in RNAlater stabilization 
reagent (Qiagen, Hilden, Germany) and stored at −80°C for 
messenger RNA (mRNA) preparation, and the other was 
placed in 4% formaldehyde for histological evaluation using the 
Geboes scoring system.12 Peripheral venous blood samples were 
taken from all study participants at the time of endoscopy for 
the assessment of systemic inflammatory status and to obtain 
genomic DNA.
RNA Extraction and Genome-Wide 
Transcriptomic Analysis
Sixty-seven biopsies (∼25 mg/biopsy) were lysed in 300 μL 
of RNeasy Fibrous Tissue kit (Qiagen) RLT buffer  (Qiagen) 
and 0.14 M of β-mercaptoethanol (β-ME; Sigma-Aldrich, St 
Louis, MO, USA) and then homogenized by centrifugation at 










Extent of disease  
(E1/E2/E3)
Extent at index 
colonoscopy









No treatment 3 (17) 4 (22)
5-ASA 15 (83) 10 (56)
Azathioprine 3 (17)
Biological therapy 1 (5)
Smoking status,  
No. (%)
Current smoker 3 (17) 3 (17)
Ex-smoker 7 (39) 5 (29)







There was no significant difference in age and sex. Extent of disease is based on 
Montreal classification. Microscopic inflammatory status of the rectum was verified 
by histopathology assessment using Geboes scoring (0 = no abnormality; 1.1 = mild 
but unequivocal increase in chronic inflammatory infiltrate; 1.2 = moderate increase 
in chronic inflammatory infiltrate). 
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10,000g through a Qiashredder column (Qiagen). Protein was 
removed by incubation for 10 minutes at 55°C with 10 μL of 
Proteinase K (20 mg/mL; >600 mAU/mL; Qiagen). Total RNA 
was extracted on RNeasy Mini-Spin Columns, and DNA was 
removed with RNase-Free DNase Digestion (Qiagen). Samples 
were taken forward for further assessment if  there was an RNA 
concentration of >25 ng/μL using the Qubit 2.0 fluorometer. 
All samples analyzed were optimized with ethanol precipitation 
to achieve an RNA integrity number of >7.0 using an Aligent 
2100 bioanalyzer or optical density ratio of >1.8 OD260/OD280 
and >1.8 OD260/OD230.
For each biopsy sample, 250 ng of total RNA was ampli-
fied and purified using the Illumina TotalPrep-96 RNA ampli-
fication kit (Ambion; Life Technologies, Carlsbad, CA, USA). 
Biotin-labeled complementary RNA (750  ng at 150  ng/μL) 
was hybridized to Illumina HumanHT-12v4 Expression 
BeadChips (Illumina, San Diego, CA, USA) for 16 hours at 
58°C. After hybridization, BeadChips were washed and stained 
with streptavidin-Cy3 (GE Healthcare, Little Chalfont, UK), 
scanned using the BeadArray reader (Illumina), and processed 
using Illumina Genome Studio software.
Bioinformatic Analysis of the Genome-Wide 
Transcriptomic Data
For each individual, our multi-omic data set con-
tains both exome sequencing data and transcriptomic profile 
data from 1 or more biopsies from the ascending colon and/
or rectum. Allele-sharing distance analysis revealed 1 dupli-
cate exome, and so after removing the corresponding individ-
ual from the data set, 35 remained: 18 cases and 17 controls. 
Analyses were performed using Python 2.7 and R, version 3.3. 
The FactoMineR R package13 was used for principal compo-
nent analyses (PCAs).
Exome Sequencing Data Analysis
Indexed paired-end libraries were prepared using the BGI 
59 Exome Enrichment Kit, and 2×150 base pair (bp) sequenc-
ing was performed by BGI on the Illumina HiSeq 2000 sys-
tem. Read alignment and variant calling of the exomes were 
performed simultaneously with ~5K other exomes using an 
in-house next-generation sequencing analysis pipeline.14 Reads 
were aligned to the human reference genome using hg37 by 
Novoalign (version 3.02.08), and variants were called by the 
Genome Analysis Toolkit (GATK) according to best practices, 
that is, local realignment around InDels, followed by joint vari-
ant calling and variant quality score recalibration.15 Further 
requirements for quality assurance included:
 1. genotyping quality (GQ) ≥20;
 2. reference/alternate read depth for heterozygote calls does not 
diverge significantly from 50:50 (chi-square test P ≥ 0.001);
 3. alternate read depth for heterozygote and homozygote alternate 
calls ≥3;
 4. GATK Variant Quality Score Recalibration (VQSR) truth tranche 
≤99.5% for single nucleotide polymorphsims (SNPs) and ≤99.0% for 
InDels;
 5. no-call rate in our samples ≤0.25;
 6. genotypes do not diverge significantly from the Hardy-Weinberg 
Equilibrium (chi-square test, P ≥ 5×10–8).
Variants were annotated by the Variant Effect Predictor 
(VEP; version 76).16
An ancestry PCA was performed on the Icelandic exomes 
(ICE) to confirm their ancestry as European and homogeneous. 
Around 5000 independent common SNPs (minor allele fre-
quency [MAF]  ≥  5%) from across the exome were used, plus 
1000 Genomes Project samples from European, East Asian, 
and African populations.16 In addition, the allele-sharing dis-
tance (ASD) in these SNPs was calculated for each sample pair 
within the ICE, British in England and Scotland (GBR), and 
Toscani in Italy (TSI) populations, and then 1-way ANOVAs 
were used to indicate whether (1) Icelandic samples are rela-
tively genetically homogeneous compared with other European 
subpopulations; (2) a difference exists in the within- vs between-
group relatedness of UCs and HCs. Note that for (1), no firm 
conclusions can be drawn because the sample size is small and 
the GBR and TSI samples were sequenced separately (by the 
1000 Genomes Project). If  (2) showed a difference, then it 
would be a potential source of bias in downstream analyses.
Potentially damaging variants were identified by the fol-
lowing filters:
 1. frameshift, stop gain, splice site changes, and missense variants pre-
dicted as damaging by 1 or more of the following: SIFT, PolyPhen-2,17 
Condel,18 CAROL,19 Combined Annotation Dependent Depletion 
(CADD)20 algorithms. Standardized cutoff for pathogenicity predic-
tion cited by the authors was used to identify potentially damaging 
variants. For PolyPhen-2 predictions, the “probably damaging” and 
“possibly damaging” categories were considered damaging.
 2. minor allele frequency (MAF) <0.05 in Kaviar21 and in non-Finnish 
Europeans in the Exome Aggregation Consortium (ExAC)22 data-
base and Genome Aggregation Database (gnomAD).
 3. present in at least 25% of our cases.
Each variant was tested for association with UC vs the 
sequenced healthy controls and using previously published 
Icelandic allele frequencies using the Fisher exact test.23
Transcriptome Expression Microarray Analysis
The original expression data contained 47,198 probes and 
57 samples: 27 ascending colon and 30 rectal taken from the 35 
individuals. For ascending colon samples, there were 12 cases 
and 15 controls, and for rectal samples, 15 cases and 15 controls.
These data were log2-transformed, quantile-normalized, 
and analyzed in R using various Bioconductor packages.24, 25
Probes with a minimum detection P value of <0.01 in at 
least 2 biopsies were retained (n = 22,716). Two case samples (1 
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detected probes were excluded. Retained probes were mapped 
to gene IDs by the illuminaHumanv4.db package. Adjustment 
of the expression data for chip-level batch effects was done by 
the empirical Bayes method ComBat26 (sva R package).27 The 
recorded bowel sites were verified by examining expression of 
genes known to significantly differ between the ascending colon 
and rectum and through a PCA on all probes (data not shown): 
1 ascending colon and 2 rectal samples demonstrated discor-
dant expression from what was expected and were removed. 
Post-quality control (QC), there were 52 samples (24 cases, 28 
controls), of which 25 were ascending colon (11 cases, 14 con-
trols) and 27 were rectal (13 cases, 14 controls).
Differential expression analysis was performed with the 
LIMMA package.28 For each bowel location, samples were 
grouped by disease status (case vs control or Montreal classifi-
cation29), and P values were adjusted for multiple testing by the 
Benjamini-Hochberg procedure (adj P value).30 Ancestry was 
controlled for by using coordinates from the exome data PCA 
as covariates.
For gene ontology (GO) and Kyoto Encyclopedia 
of Genes and Genomes (KEGG) analysis, STRING31 was 
employed. Where a transcript had 2 probes or more, the probe 
with the highest fold change or expression values was used for 
analysis. Pathway analyses were also conducted using DAVID 
Bioinformatics Resources 6.732, 33 and WebGestalt34 to ensure 
consistency of results.
Determination of Gene Expression Influence by 
Predicted Damaging Variants
Differential expression analysis was performed with the 
LIMMA package. For each damaging variant, samples were 
grouped by wild-type or carrier of the variant, and P values 
were adjusted for multiple testing by the Benjamini-Hochberg 
procedure.
Integrated Multi-omic and Clinical Data Analysis
Differential expression analysis was also performed where 
samples were grouped by genotype for prioritized potentially 
damaging coding variants. A  further PCA was performed on 
the multi-omic and clinical data together. The latter included 
sex, microscopic inflammation score, disease status, disease 
extent (Montreal classification for each patient), treatment sta-
tus, hemoglobin, neutrophil count, lymphocyte count, albumin 
(ALB), C-reactive protein (CRP), alkaline phosphatase (ALP), 
gamma glutamyl transferase (ɣGT), aspartate transaminase 
(AST), alanine transaminase (ALT), and bilirubin. The aim 
was to assess the relative utility of these various data.
RESULTS
Assessment of Ancestry and Relatedness
In the ancestry PCA, the Icelandic samples (ICE) 
clustered together in close proximity to the 1000 Genomes 
Project GBR and Utah Residents (CEPH) with Northern 
and Western Ancestry samples (Supplementary Fig.  1), 
confirming their ancestry as European and homogeneous. 
In the assessment of  relatedness, there was a difference 
(P < 0.0005) in the mean ASD of  GBR, TSI, and ICE sam-
ples (Fig. 1A). According to Tukey’s honest significant dif-
ference method, there was a significant difference between 
ICE and both GBR and TSI (P  <  0.005 and P  <  0.0005), 
but not between GBR and TSI. In line with other studies, 
this suggests that the Icelandic population is relatively genet-
ically homogenous, but as stated in the “Methods,” no firm 
conclusions can be drawn. There was no significant differ-
ence in the mean ASD of  HC, UC-HC, and UC (Fig. 1B), 
thus providing confidence that downstream analyses are not 
confounded by a difference in the within- vs between-group 
relatedness of  UCs and HCs.
Identification of Rare and Damaging Mutations 
in the Icelandic UC Cohort
Exome sequencing resulted in the identification of 
12,483 predicted damaging variants within the entire cohort 
(n = 35). Further filtering based on our bespoke filtering (see 
the “Methods”) reduced this to 238; of  these variants, 48 had 
a CADD score greater than 20, and 38 were deemed to have 
a high impact on gene function based on VEP consequence 
descriptors (Supplementary Table 1).35 Where available, com-
parisons were also made with the Decode Icelandic whole-ge-
nome database (n  =  2363), available from the European 
Variant Archive (PRJEB8636).23 It was possible to test for 
enrichment in our cohort compared with the Icelandic pop-
ulation for 50 of  the 252 variants within our total cohort. 
We identified 2 damaging missense mutations in thiopurine 
S-methytransferase (TPMT), A154T/rs1800460, and Y240C/
rs1142345, in 8 out of  18 UC patients (44%), and 2 out of  17 
(12%) healthy controls (Supplementary Table 2). All 8 patients 
were found to be heterozygous, with an MAF of  0.22 for both 
variants compared, with the reported Icelandic population 
frequency of  0.062 and 0.063, respectively (Decode data set). 
Overall the Icelandic population has a higher MAF for both 
variants in TMPT compared with the non-Finnish European 
population (MAF, 0.03 and 0.04, respectively). These 2 vari-
ants are in ~100% linkage disequilibrium (LD) in the Icelandic 
population and are known to result in a loss of  enzyme func-
tion leading to high levels of  toxic metabolites from thiopu-
rine analogues, which cause liver toxicity and bone marrow 
suppression.36, 37
Predicted Damaging Variants in Genes Identified 
by Previous GWAS Studies
To date, 240 loci have been identified associated with IBD 
by GWAS.1 Of the 248 predicted damaging variants identified 
as enriched within the Icelandic UC patients, 7 were located 
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CD226, F5, SKAP2, INFG, NXPE1, and SLC39A11. Only the 
variants in SLC26A3 and F5 had a CADD score above 20, and 
none of these reached significance after correction for multiple 
testing.
Characteristics and Inflammatory Status of UC 
Patients
Summary characteristics of the study cohort are recorded 
in Table 1. The serum levels of inflammatory markers CRP and 
albumin, in addition to circulating peripheral neutrophil num-
bers, were not significantly different between the HC and UC 
cohorts (Fig. 2A). In addition, all other parameters tested were 
similar between the HC and UC (see the “Methods,” data not 
shown). A  PCA of the entire blood results demonstrated no 
difference between the HC and UC groups (data not shown). 
MAYO scoring of all patients confirmed the quiescent nature 
of the disease activity, with 5 patients having a MAYO score 
of 1 identified in the rectum and all other patients scoring 
0. Histological assessment of the rectal and ascending colonic 
biopsies revealed microscopic inflammatory activity in 5 of the 
UC biopsy samples from the rectum and none in the ascending 
colon. The microscopic activity within the rectum was 1.1 in 4 
patients and 1.2 in 1 UC patient, with all other biopsies scor-
ing 0 using the Geboes scoring system. PCA did not separate 
this cohort from the microscopically noninflamed UC biop-
sies. None of the HC biopsies were found to have microscopic 
inflammation or any other pathological abnormalities. On 
review of the medical records for the control subjects 5 years 
after the biopsies were collected, none had developed IBD or 
any other colonic pathology.
Identification of Different Inflammatory 
States Within the Rectum of UC Patients Using 
Transcriptomics
Previous studies conducted on inflamed biopsy material 
from UC patients by Noble et al. identified an inflammatory gene 
signature.38 The major inflammatory markers were reported to 
be SAA1, S100A8, S100A9, DEFA5, DEFA6, and IL-8. We 
examined the expression of these genes in our Icelandic cohort 
to ascertain the inflammatory status of the rectum and ascend-
ing colon at the transcriptomic level (Fig. 2B). One individual 
demonstrated an elevation in DEFA5 and DEFA6 (Fig.  2B). 
Three of 6 individuals with microscopic inflammation had ele-
vated levels of S100A8 and S100A9 when compared with the 
average of the cohorts. The remaining 9 UC patients and all of 
the HCs (n = 15) were found to have similarly low levels of all 
6 inflammatory markers. Overall there was no significant group 
difference in the expression of the classical inflammatory genes 
between the UC and HC groups.
Change in Global Transcriptomic Profile in 
UC Rectum
Principal component analysis and differential gene anal-
ysis were performed on the entire UC (n = 18) and HC (n = 16) 
transcriptomic data sets (n = 22,716 probes). Principal compo-
nent analysis separated the samples by site of biopsy and dis-
ease status (Fig. 3). Differential analysis comparing rectal gene 
expression in UC and HC subjects identified 1838 differentially 
expressed genes, of which 935 genes were overexpressed and 
903 underexpressed in the disease cohort (adj P < 0.05) (Fig. 4; 
Supplementary Table 3).
FIGURE 1. Box plots of pairwise ASD across the exome in sample groups. A, 1000 Genomes Project GBR population, all samples in this study (ICE), 
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The GO and KEGG pathway analysis of the upregu-
lated probes (n = 935) within the rectal tissue of Icelandic UC 
patients revealed an enrichment for ribosomes (KEGG path-
way 03010; false discovery rate, 0.00098) and protein process-
ing in the endoplasmic reticulum (KEGG pathway 04141; false 
discovery rate, 0.00628) (Table 2).39–42 Analysis of the biologi-
cal process and molecular process of gene ontology identified 
2 groupings that have been previously established as important 
in the pathogenesis of UC, including unfolded protein response 
(UPR)43 and macroautophagy44 (Supplementary Fig. 2).
Ascending Colon Transcriptomic Data
Differential analysis identified 184 differentially expressed 
gene probes between ascending colonic tissue from the UC and 
HC cohorts. Sixty-three genes were upregulated, and 121 genes 
were downregulated. No GO or KEGG pathways were signifi-
cantly enriched, and STRING analysis was not able to identify 
any significant groupings.
The confluent distal to proximal colonic inflammation 
characteristic of UC provides the opportunity to assess areas 
of the bowel with repeated episodes of inflammation with 
more proximal areas that were likely to have a reduced bur-
den of inflammation or no inflammation at all. To identify if  
there was evidence of an intrinsic transcriptomic signature that 
was independent of inflammation, we compared the differen-
tial transcriptomic analysis of the ascending and rectal biop-
sies. Thirty-seven gene probes were identified as overlapping in 
both groups of transcriptomic data (Supplementary Table 4). 
FIGURE 3. PCA of microarray transcriptome data from bowel biopsies: The biopsies are distinguished by location (ascending colon [circle] or rectum 


































































































































































FIGURE 2. Assessment of inflammatory status of UC patients and controls. A, Systemic inflammatory markers from peripheral blood samples taken 
from subjects on the day of endoscopy (CRP, Hb). B, Rectal biopsy transcriptomic profiles of known inflammatory genes for all UC and HC subjects 
(SAA1, serum amyloid 1; S100A8, S100 calcium binding protein A8; S100A9, S100 calcium binding protein A9; DEFA5, defensin A5; DEFA6, defensin 
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Fifteen genes were underexpressed and 22 overexpressed, and 
all but 1 gene had the same directional fold change in both 
areas of the bowel. The genes identified primarily relate to cell 
cycle, ribosomes, transcription factors, and cytoskeleton forma-
tion. There was no significant GO term enrichment for these 
groups of genes.
Potential Impact of the Rare Damaging Variants 
on Rectal Gene Expression
There was no significant difference in the burden of 
damaging variants when comparing the UC group and the 
HC group (data not shown). Through a combined analysis 
of exome variants and transcriptomic data, we were able to 
FIGURE 4. Differential gene analysis of noninflamed rectal biopsies from UC patients and HCs. A, Volcano plot of all HC vs UC rectal genes. Genes 
colored red are significantly different, with an adjusted P < 0.01. B, Heatmap of the 50 most differentially expressed genes between UCs and HCs 
(according to adj P value), where the color scale for relative expression level is from low (red) to high (white).
TABLE 2. Gene Ontology and KEGG Pathway Analysis of Differential Genes From the Rectum
Pathway ID Pathway Description Count in Gene Set False Discovery Rate
KEGG Pathway
03010 Ribosome 13 0.000982
04141 Protein processing in endoplasmic reticulum 13 0.00628
05016 Huntington’s disease 12 0.0483
Biological process (GO)
GO:0044237 Cellular metabolic process 237 1.65e-11
GO:0043170 Macromolecule metabolic process 214 3.23e-11
GO:0044260 Cellular macromolecule metabolic process 202 3.23e-11
GO:0071704 Organic substance metabolic process 233 9.17e-09
GO:0044238 Primary metabolic process 228 1.45e-08
Molecular process (GO)
GO:0003723 RNA binding 78 7.68e-11
GO:0044822 Poly(A) RNA binding 66 7.68e-11
GO:0003676 Nucleic acid binding 121 1.99e-05
GO:1901363 Heterocyclic compound binding 159 4.14e-05
GO:0097159 Organic cyclic compound binding 160 4.67e-05
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determine if  rare predicted damaging variants observed within 
the UC cohort had any influence on rectal gene expression. 
Within the group of 248 prioritized variants, several were found 
to have a potential influence on rectal and ascending colon gene 
expression. Individuals that carry the 2 TPMT mutations had a 
decreased expression of speckle type BTB/POZ protein (SPOP; 
adj P < 0.05) (Fig. 5B). Carrying the mutation C307W in the 
SLC26A3 gene was associated with an increase in expression of 
both the dual oxidase 2 (DUOX2) and dual oxidase maturation 
factor 2 (DUOXA2; adj P < 0.05) (Fig. 5D and E).
DISCUSSION
Ulcerative colitis is a complex disease with both genetic 
and environmental factors contributing to its pathogenesis. 
Previous genetic studies have identified large numbers of com-
mon genetic variants that together are thought contribute to an 
increased risk of developing UC via modulation of pathways 
and processes. To identify the pathways and processes that are 
abnormal in UC, it is preferable to study a population with a 
high disease incidence that is ethnically homogeneous and from 
a similar environment. The Icelandic population fulfills these 
requirements. By studying exome and transcriptomic data from 
Icelandic UC patients, we have provided evidence to support 
an alteration in colonic mucosal homeostasis and the upregula-
tion in pathways of protein processing within the endoplasmic 
reticulum.
Genomic data from the Icelandic cohort under study 
have reconfirmed the narrowed heterogeneity described by 
Helgason et al.9 showing a nonrelated but genetically restricted 






























































FIGURE 5. Variant impact on downstream transcriptomics. A, Rectal expression of TPMT is not affected by the 2 observed TPMT variants (A154T/
Y240C), (B) whereas the variants demonstrate a significant downstream impact on SPOP expression within the rectum. C, Expression of SLC26A3 
within the colon is not affected by variant status (C307W), but (D) and (E) carriers of this mutation demonstrate an increase in DUOXA2 and DUOX2 
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population. To identify genes and processes that may be impli-
cated in the disease etiology separate from the transcriptomic 
signature of inflammation, we specifically targeted patients with 
quiescent disease. The analysis of the histology, systemic inflam-
matory markers, and whole-genome transcriptomic profiling of 
our subjects demonstrated that the current cohort represents a 
clinically quiescent group of patients. These results provided us 
with confidence that our findings were not directly associated 
with an ongoing chronic inflammatory process or infiltrating 
leukocyte populations, but were associated with changes within 
the cells of the colonic mucosa. Our results demonstrated some 
overlap with a number of previous transcriptomic studies con-
ducted in different ethnic populations.5, 45 We have previously 
conducted a transcriptomic analysis on macroscopically nor-
mal bowel pinch biopsies obtained from patients in the United 
Kingdom and identified 3 abnormally expressed genes in UC 
rectal tissues.5 The Icelandic UC biopsies had a significantly 
higher number of differential genes identified; however, the 3 
previously reported genes were not among them. The lower 
number of genes identified in the UK cohort could be due to 
population diversity. Environmental effects may also play a role 
in the more uniform results in the Icelandic study, but further 
work will be needed to determine what these could be.
Despite the quiescent nature of the patient’s disease in our 
cohort, we were still able to identify a large number of transcrip-
tomic changes, particularly in the rectum. This may represent a 
specific colonic response to inflammation or its resolution. One 
of the major processes identified as overexpressed in UC rectal 
tissue was the UPR, which has been previously shown to play a 
vital role in intestinal homeostasis.46 Dysregulation in UPR has 
been described in both UC and Crohn’s disease.47 Through the 
use of transgenic animal models, the functional consequence 
of an alteration in the UPR response and the development of 
gastrointestinal inflammation has been demonstrated.43, 48 Loss 
or mutations in effectors and regulators of the UPR have been 
shown to increase the host’s susceptibility to the development 
of experimental colitis.49, 50 Reduced numbers of genes were 
found to be altered in the ascending colon compared with HCs. 
This may be as a consequence of reduced episodes of inflam-
mation or, in the majority of cases, no inflammation. A paucity 
of genes relating to UPR within the ascending colon suggests 
that these alterations in cellular stress could be a consequence 
of inflammation specifically and may not represent a “pre-in-
flammatory” change.
Exome sequencing identified 48 possibly damaging 
genetic variants with a CADD score >20 that were enriched in 
the UC patients. Several of the mutations were shown to have 
a potential influence on rectal gene expression. SLC26A3 and 
coagulation factor 5 (F5) have both previously been identified 
as risk loci in IBD GWAS studies.2, 51 SLC26A3, also known 
as the downregulated in adenoma (DRA) gene, encodes a pro-
tein essential for intestinal chloride absorption and is a trans-
membrane glycoprotein localized to the apical membrane of 
the columnar epithelium. Mutations in SLC26A3 that result in 
loss of function have been associated with congenital chloride 
diarrhea.52 A number of SNPs have been identified in SLC26A3 
associated with either UC or IBD in both East Asian and 
European populations.51, 53
The C307W mutation in SLC26A3 that we identified in 
our Icelandic UC cohort seemed to have an influence on the 
expression of DUOX2 and DUOXA2 in the rectum of patients. 
DUOX2 and DUOXA2 genes encode glycoproteins, which 
form a heterodimer and are members of the NADPH oxidase 
family. DUOX proteins are widely expressed in the apical com-
ponent of the colonic epithelium and provide a mechanism of 
bacterial and viral killing.54 DUOX2 and its maturation and 
localization factor DUOXA2 have previously been shown to be 
key in the production of hydrogen peroxide within the colon 
and to be upregulated in active colitis and colonic cancer.55 
They are considered to have an important role in the main-
tenance of the mucosal barrier and the ability to protect the 
host from pathogens.56 Recent work has identified mutations in 
DUOX2 in patients with IBD.57, 58 Further studies are needed to 
determine if  the expression of the C307W SLC26A3 mutation 
alters the DUOX2/DUOXA2 complex and has any impact on 
the colonic tissue or microbiota.
In addition to SLC26A3, the TPMT mutation A154T/
Y240C also seems to have influenced rectal gene expression. 
Individuals who carry the A154T/Y240C variant had reduced 
expression of SPOP, an E3 ubiquitin ligase adaptor protein. It 
has most widely been described in the regulation of epithelial 
cell proliferation within several different cancer models includ-
ing prostate, lung, ovarian, and renal cell carcinoma.59 SPOP is 
downregulated in colorectal cancers, and inactivation promotes 
metastasis, suggesting a role as a tumor suppressor.60 The exact 
physiological function of TPMT has yet to be elucidated; how-
ever, it is a key enzyme in the metabolism of immunosuppressive 
thiopurine analogues commonly used in the treatment of UC. 
The 2 TMPT mutations that were identified in the Icelandic UC 
cohort are in 100% LD and have previously been reported and 
given the abbreviation TMPT*3A (460G>A, rs1800460, A154T; 
719A>G, rs1142345, Y240C). TMPT metabolizes thiopurine 
drugs, with S-adenosyl-L-methionine as the S-methyl donor 
and S-adenosyl-L-homocysteine as a byproduct. TMPT*3A 
has been shown to result in a loss of enzyme function leading 
to build-up of high levels of toxic metabolites from thiopurine 
analogues, which cause bone marrow suppression and hepato-
toxicity. Genetic polymorphisms that affect enzymatic activ-
ity result in thiopurine S-methyltransferase deficiency.37 The 
increased prevalence of the TMPT variant within the Icelandic 
population and potentially the UC patients within this group 
has direct clinical relevance due to the use of thiopurine ana-
logues as immunomodulators in this disease. Twenty percent of 
patients experiencing a side effect related to bone marrow sup-
pression and leukopenia have a TPMT mutation.61 Screening 
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be advantageous. Interestingly, in a recent study from Iceland, 
azathioprine was found to be the hepatotoxic drug associated 
with the highest risk of hepatotoxicity, affecting approximately 
1 out of 130 patients treated.62 Very little is known about the 
true biological role of the TMPT, and whether it contributes to 
the pathogenesis of UC is also currently unclear.
In conclusion, our data provide the first paired exomic 
and transcriptomic data comparing patients with clinically 
quiescent UC and HC subjects. Transcriptomic analysis con-
firmed an elevation in cell cycle activity and an underlying 
UPR within the colonic tissue of UC patients. We were able to 
identify a number of predicted damaging coding variants that 
were present at frequencies higher than would be expected in 
the general Icelandic and non-Finnish European populations. 
Further studies including replication cohorts will be needed 
to determine the relevance of the variants identified to UC. 
In addition, it would be highly informative to determine the 
microbiota of the Icelandic population and UC patients. This 
and other possible environmental factors may help to uncover 
possible explanations for the increased prevalence of this dis-
ease within this population. Importantly, our findings provide 
evidence to support the theory that rare and damaging muta-
tions can also have an influence on other genes within colonic 
tissue. Our data provide further evidence of the importance of 
combined multi-omics in selective populations to appreciate the 
impact of genomic variants on human diseases.
SUPPLEMENTARY DATA
Supplementary data are available at Inflammatory Bowel 
Diseases online.
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